e-learning
resources
London 2016
Wednesday, 07.09.2016
Lung cancer: therapeutic modalities, re-staging, and follow-up
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Stefan Rüdiger (Ulm, Germany), Stefan Rudiger, Cornelia Kropf-Sanchen, Gerlinde Schmidtke-Schrezenmeier, Marta Aksentiy, Katja Hoss, Wolfgang Rottbauer
Source:
International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Session:
Lung cancer: therapeutic modalities, re-staging, and follow-up
Session type:
Poster Discussion
Number:
4845
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stefan Rüdiger (Ulm, Germany), Stefan Rudiger, Cornelia Kropf-Sanchen, Gerlinde Schmidtke-Schrezenmeier, Marta Aksentiy, Katja Hoss, Wolfgang Rottbauer. Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab. Eur Respir J 2016; 48: Suppl. 60, 4845
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Definition and history of sarcoidosis
Related content which might interest you:
ALK/EML4 translocation in non-squamous NSCLC and their predictors
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Treatment of advanced non-small cell lung cancer with trofosfamide
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Surgical treatment outcomes on early-stages of non-small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Algorithm of preoperative N-staging of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Electrospray-mediated local chemotherapy of lung carcinoma in mice
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Molecular profiling of lung squamous carcinogenesis
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
The prognostic value of D-dimer in lung carcinoma
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Outcomes of radical treatment of early stage non-small cell lung cancer
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Improving survival for NSCLC patients in the national lung cancer audit
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Does IASLC/ATS/ERS classification of lung adenocarcinoma impacts prognosis?
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Locoregional recurrence after pulmonary segmentectomy of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept